About Us

The Roche Group owns the entire shares of Genentech in the USA and the majority shares of Chugai Pharmaceutical in Japan.

Encouraging scientific approaches and adapting innovative ideas, Roche, as a research-oriented company, utilizes the latest technologies and discoveries while developing its products. By investing 14 billion Swiss francs in R&D in 2022, Roche is among the top 9 investors in R&D among all industries and ranks 1st in health R&D.

Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices for the 15th time in a row, based on the long-term perspective it adopts in its fields of activity. This is a result of Roche's efforts to increase access to healthcare in every country where it operates, with local collaborations.

In addition, more than 30 medicines developed by Roche, including life-saving antibiotics, antimalarials and cancer drugs, are on the World Health Organization's Model List of Essential Medicines.

Launched in 1958, Roche Pharmaceuticals has been providing treatment solutions to Turkish physicians and patients with more than 250 employees and innovative products. Since 2015, it has been conducting its operations from its head office in Maslak-Uniq, Istanbul.

With the innovative solutions it provides, Roche Diagnostics enables patients to benefit more from their treatment processes with the vision of innovating  diagnostics, shaping healthcare and changing lives. It improves patients' lives with its innovative and advanced technology-based devices for professional and personal use, biochemistry, hormone, genetic, molecular and cancer testing portfolio in the fields of Centralised & Point-of-Care Solutions, Molecular Solutions and Diabetes Care.

Operating in Turkey since 1991, Roche Diagnostics carries out its activities from its head office in Istanbul Metro City with more than 250 employees.